{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:47:43Z","timestamp":1760453263874,"version":"3.37.3"},"reference-count":43,"publisher":"Informa UK Limited","issue":"20","license":[{"start":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,6,23]]},"DOI":"10.1080\/14796694.2024.2351352","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T12:37:09Z","timestamp":1721997429000},"page":"1385-1392","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6072-7508","authenticated-orcid":false,"given":"Maria","family":"Jakobsson","sequence":"first","affiliation":[{"name":"Pfizer AB,\u00a0113 63 Stockholm,\u00a0Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5491-0143","authenticated-orcid":false,"given":"Angela","family":"Strambi","sequence":"additional","affiliation":[{"name":"Fondazione Toscana Life Sciences,\u00a053100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1905-4047","authenticated-orcid":false,"given":"Fredrik","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Pfizer AB,\u00a0113 63 Stockholm,\u00a0Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8105-3486","authenticated-orcid":false,"given":"Johannes","family":"Arpeg\u00e5rd","sequence":"additional","affiliation":[{"name":"Pfizer AB,\u00a0113 63 Stockholm,\u00a0Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Dal\u00e9n","sequence":"additional","affiliation":[{"name":"ICON plc,\u00a0111 22 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1279"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113205"},{"key":"e_1_3_8_5_1","unstructured":"ESMO. eUpdate \u2013 renal cell carcinoma treatment recommendations 2021 [cited 2023 February 20 ]. Available from: www.esmo.org\/guidelines\/genitourinary-cancers\/renal-cell-carcinoma\/eupdate-renal-cell-carcinoma-treatment-recommendations-4"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71222-7"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2530"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006017.pub2"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.82"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0001"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3617"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70093-7"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyp174"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21907"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyp305"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2047-4"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-020-00809-z"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.04.015"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.076"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.3233\/KCA-220011"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48087-4"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.014"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0104-z"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.05.013"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.119"},{"key":"e_1_3_8_28_1","unstructured":"Agency SDaPB. Inlyta is included in the high-cost protection 2013 [cited 2023]. Available from: www.tlv.se\/beslut\/beslut-lakemedel\/generell-subvention\/arkiv\/2013-02-08-inlyta-ingar-i-hogkostnadsskyddet.html"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_3_8_30_1","doi-asserted-by":"crossref","DOI":"10.1080\/14796694.2024.2401309","article-title":"First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population","author":"Jakobsson M","year":"2024","unstructured":"Jakobsson M, Nilsson F, Strambi A, et al. First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population. Future Oncol. 2024.","journal-title":"Future Oncol."},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz060"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9064"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4921"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29397"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/cci.20.00125"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0421"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.06.019"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.09.006"},{"key":"e_1_3_8_39_1","unstructured":"ESMO. eUpdate \u2013 Renal Cell Carcinoma Treatment Recommendations 2021 [cited 2022 3 October]. Available from: www.esmo.org\/guidelines\/genitourinary-cancers\/renal-cell-carcinoma\/eupdate-renal-cell-carcinoma-treatment-recommendations-4"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.790"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5060"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30513-3"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0164-0"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30735-1"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS707"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2351352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T21:56:03Z","timestamp":1732485363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2351352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,23]]},"references-count":43,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,6,23]]}},"alternative-id":["10.1080\/14796694.2024.2351352"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2351352","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2024,6,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}